Sergey Mamchur

Dr. Sergey Mamchur


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Interventional Medicine and Applied Science
Verified
Journal Article
Open access
SMSergey Mamchur
Sergey Mamchur
IMIrina N. Mamchur
Irina N. Mamchur
EKEgor A. Khomenko
Egor A. Khomenko
NBNikita S. Bokhan
Nikita S. Bokhan
DSDiana A. Scherbinina
Diana A. Scherbinina
The aim of the study was to compare the efficacy of pulmonary vein antrum isolation (PVAI), extended PVAI and ganglionic plexi (GP) ablation in persistent AF. Methods: One hundred and twenty patients 56.2 ± 8.8 years old were randomized into three groups: GP ablation (n = 37), PVAI (n = 42), and extended PVAI (n = 41). The following parameters were studied: sinus rhythm restoration, vagal reactions, fluoroscopy time, procedure duration, lesion surface area. In 16 months after the procedure, echocardiography and Holter monitoring were performed. Results: Significant differences were found in the amount of X-ray exposure, procedure duration, lesion surface area and vagal reactions. In all the cases, atrial mechanical function worsened after the procedure. However, there were no significant differences between the groups. Sixteen months after the procedure, sinus rhythm without antiarrhythmic therapy was maintained in 38% of patients in GP group, in 56% of patients in PVAI group and in 69% of patients in extended PVAI group. Conclusions: In persistent AF, the extended PVAI is more effective than PVAI and GP ablation. After the PVAI or extended PVAI, abnormalities of the left atrial mechanical function occurred if the lesion area exceeded 25% of the total LA surface area.

26 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMSergey Mamchur
Sergey Mamchur
TCTatiana Chichkova
Tatiana Chichkova
EKEgor Khomenko
Egor Khomenko
AKAlexander Kokov
Alexander Kokov
The aim of this paper is to evaluate the effect of pulmonary vein (PV) morphometric characteristics and spatial orientation on the results of cryoballoon ablation (CBA). Methods: A randomized, prospective, single-center controlled study was conducted, enrolling 230 patients with drug-refractory atrial fibrillation (AF). We compared procedural and long-term outcomes in patients who underwent their first procedure of pulmonary vein isolation (PVI) for AF with either radiofrequency ablation (RFA) (n = 108) or CBA (n = 122) and assessed their interaction with the different pattern of PV anatomy, morphometric characteristics, and spatial orientation. The primary efficacy endpoint was any documented atrial arrhythmia recurrence (AF, atrial flutter, or atrial tachycardia) lasting over 30 s during a 12-month follow-up after a 90-day blanking period and discontinuation of antiarrhythmic drugs. The procedure’s endpoint was the achievement of PVI. Before the intervention, all patients underwent computed tomography (CT) to assess the PV anatomical variant, maximum and minimum diameters of the PV’s ostia, their cross-sectional area, orifice ovality index, and PV tilt angles. Results: The mean follow-up period was 14 months (12; 24). Long-term efficacy in the cryoablation group was 78.8% and in the RFA group—83.3% (OR = 0.74; 95% CI 0.41–1.3; p = 0.31). The RFA results did not depend on PV anatomy. The «difficult» occlusion of the right inferior PV (RIPV) occurred in 12 patients and was associated with a more horizontal PV position in the frontal plane; the mean tilt angle was −15.2 ± 6.2° versus −26.5 ± 6.3° in the absence of technical difficulties (p = 0.0001). In 11 cases (9%), during ablation of the right superior PV (RSPV), phrenic nerve injury (PNI) occurred and was associated with the maximum and minimum RSPV diameter, 20.0–20.4 mm (OR = 13.2; 95% CI: 4.7–41.9, p < 0.05) and 17.5–20 mm (OR = 12.5; 95% CI 3.4–51, p < 0.05), respectively. Patients with arrhythmia recurrence were characterized by significantly larger diameters and ovality of the left superior PV (LSPV). The spatial orientation of the PV does not affect the long-term results of cryoablation. Conclusion: Preprocedural evaluation of PV morphology and orientation using cardiac CT might help choose the optimal technology for the individual patient.

14 August 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EME. N. Mikhailov
E. N. Mikhailov
NGN. Z. Gasymova
N. Z. Gasymova
SBS. А. Bayramova
S. А. Bayramova
VKV. E. Kharats
V. E. Kharats
OKO. N. Kachalkova
O. N. Kachalkova
ESE. V. Shlyakhto
E. V. Shlyakhto
Aim. The results presented, of subanalysis of the catheter ablation (CA) registry in atrial fibrillation (AF) with the patients properties, specifics of CA and treatment results, in Russia comparing to European countries.Material and methods. During 2012 to 2015, totally 3742 patients included to the registry, of those 477 in Russia. In 467 Russian patients (males 56,5%; mean age 58,5 y. o.) CA AF was done. During one year 392 patients were followed up. Minimum requirements to follow-up: routine ECG registration and non less than one contact after 12 months passed.Results. In Russian patients there were more common obesity (46,1% and 29,2%, p<0,001), hypertension heart disease (40,2% and 22,8%, p<0,0001), coronary heart disease (31,7% and 16,2%, p<0,0001), chronic heart failure (67,3% and 13,0%, p<0,0001). In Russia the patients more commonly underwent primary CA (83,5% in Russia and 77,6% in European countries, p<0,05), more rare in Russia the cryoballoon ablation was done (3% and 18%, p<0,05). Generally adverse events were reported more rare in Russia (10,5% and 16,6%, p=0,0007), including cardiovascular adverse events (2,6% and 5,2%, p<0,05). Tachiarrhythmias recurs were diagnosed more rare in Russia, including by the subsutaneous ECG monitors (17% and 1,6% in other countries, р<0,001). Within the year of follow-up, full absence of tachiarrhythmias recurs in Russia was found in 65,8% of patients, in other countries — in 74,7% (р=0,0003).Conclusion. In real clinical setting, high efficacy of CA AF was shown, resistant to antiarrhythmic therapy. In most of Russian patients there were cardiovascular comorbidities. There was lower rate of reported adverse events in Russian centers of interventional treatments.

14 September 2012 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
SMSergey Mamchur
Sergey Mamchur
MKMikhail Y. Kurilin
Mikhail Y. Kurilin

8 June 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
EMEvgeny N Mikhaylov
Evgeny N Mikhaylov
LKL. E. Korobchenko
L. E. Korobchenko
SBS. A. Bayramova
S. A. Bayramova
VKV. E. Kharats
V. E. Kharats
OKO. N. Kachalkova
O. N. Kachalkova
ЕМЕ. Н Михайлов
Е. Н Михайлов
Aim. Catheter ablation (CA) is an effective approach for rhythm control in atrial fibrillation (AF), however antiarrhythmic therapy (AAT) remains important. There is a lack of data about long-term AAT use after CA. This study evaluates AAT after CA for AF.Material and methods. In 2012-2016, EURObservational Research Programme of Atrial Fibrillation Ablation Long-Term (EORP AFA L-T) registry was conducted, which included 476 Russian patients (57,1% — men; mean age — 57,1±8,7 years). The follow-up after CA was 12 months (available in 81,9% of patients). The use of AAT was evaluated prior to hospitalization, during hospitalization for CA, as well as at 3, 6 and 12 months of follow-up.Results. Prior to CA, 439 (92,2%) patients received AAT During CA, 459 (96,4%) patients were treated with AAT. After CA, AAT was used by 463 (97,3%), 370 (94,8%), and 307 (78,7%) patients at 3, 6 and 12 months of follow-up, respectively. There was no arrhythmia recurrence in 187 (47,9%) subjects. Among these patients, 40 (21,4%) received class IC or III AAT. The peak of AAT use was found for class IC agents within 3 months after CA (P<0,05), while for other drugs this trend was not observed. There were no factors associated with AAT usage in patients without arrhythmia recurrence after CA. A positive correlation of arrhythmia non-recurrence with a minimum number of previously used antiarrhythmic agents was revealed (RR=0,85; 95% CI 0,73-0,98; P=0,03).Conclusion. The frequency of AAT use after AF ablation is significantly reduced. However, there is a cohort of patients without documented arrhythmia recurrence still receiving AAT, which requires special attention of physicians. There were no clinical predictors of continued AAT in subjects without arrhythmia recurrence.

1 August 2014 in Journal of the Chinese Medical Association
Verified
Journal Article
Closed access
SMSergey Mamchur
Sergey Mamchur
IMIrina N. Mamchur
Irina N. Mamchur
EKEgor A. Khomenko
Egor A. Khomenko
EGElena Gorbunova
Elena Gorbunova
ISIrina N. Sizova
Irina N. Sizova
YOYury N. Odarenko
Yury N. Odarenko
BackgroundPatients with mitral valve (MV) disease and atrial fibrillation (AF) undergo simultaneous prosthetic valve replacement and radiofrequency (RF) ablation procedure; however, this combinational procedure restores sinus rhythm (SR) in only 68–82% of the cases. In patients with ineffective surgical ablation, the use of a biological prosthetic valve might not only be a good choice to perform safe catheter ablation procedure in the left atrium (LA), but also provide a way to discontinue administration of oral anticoagulants. The objective of this study was to assess the efficacy of catheter ablation for AF after MV replacement with a biological prosthesis and an ineffective surgical ablation procedure.MethodsTen consecutive patients aged 48 ± 7 years were enrolled in this study. All patients had long-persistent AF associated with a rheumatic valve disease, which was treated by MV replacement with a biological prosthesis and a surgical RF ablation procedure. In the late postoperative period, all the patients had recurrent hemodynamically significant AF, which required repeated cardioversions. From 1 year to 3 years after the surgery, catheter ablation was performed, including reisolation of pulmonary veins (PVs) with the ablation of ganglionic plexi or linear lesions on the roof of the LA and mitral isthmus. The efficacy was assessed at 3 months, 6 months, and 12 months after the procedure.ResultsRestoration of SR during ablation was achieved in all of the cases. In 6–9 months, all the patients were free of arrhythmia. LA stunning manifested by the absence or decrease of the “A” wave in the transmitral flow and the retrograde wave in the PV flow was observed in nine patients with SR. In five of the patients, LA contractile function was restored in 1–6 months. Prosthetic valve dysfunction was not detected in any of the patients.ConclusionCatheter ablation is an effective method for AF treatment following an ineffective surgical RF ablation procedure and biological prosthetic MV replacement. The use of bioprosthetic MVs allows for performing safe catheter ablation without subsequent prosthetic dysfunction